Evidence map›Paper›PMID 42665427›Full record

ArticleIn vivo (Athens, Greece)

Clinical Impact of Albumin-Bilirubin (ALBI) Score in Patients With Recurrent Esophageal Cancer After Curative Treatment.

Taiichi Kawabe, Toru Aoyama, Itaru Hashimoto, Yukio Maezawa, Sho Sato, Takashi Kosaka, Miki Kayashima, Maki Takagi, Kohei Sekiguchi, Kiyoko Shimada and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Taiichi Kawabe *Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Toru Aoyama *Department of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan; aoyamat@yokohama-cu.ac.jp.
Itaru HashimotoDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan; hashimoto.ita.ic@yokohama-cu.ac.jp.
Yukio MaezawaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Sho SatoDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Takashi KosakaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Miki KayashimaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Maki TakagiDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Kohei SekiguchiDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Kiyoko ShimadaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Naoko OkudaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Momoko FukudaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Masaki TakahashiDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Mihwa JuDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Natsumi KamiyaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Yosuke AtsumiDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Keisuke KazamaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Nobuhiro SuganoDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Ayako TamagawaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Aya SaitoDepartment of Surgery, Yokohama City University, Yokohama, Japan.
Takaki YoshikawaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.
Norio YukawaDepartment of Gastrointestinal Surgery, Yokohama City University, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe albumin-bilirubin (ALBI) score, which evaluates pretreatment liver function, has been reported as a prognostic factor in several malignancies. We conducted a retrospective study to clarify the prognostic impact of the ALBI score in patients with recurrent esophageal cancer. PATIENTS AND

methodsWe retrospectively reviewed the medical records and data of consecutive patients with recurrent esophageal cancer who received treatment, including best supportive care, at Yokohama City University from 2005 to 2022. The primary endpoint of the present study was overall survival (OS) after recurrence. The secondary endpoint was the association between the ALBI score and the treatment course after recurrence.

resultsNinety patients were eligible for the present study. The median overall survival was 10.4 months (95% confidence interval=4.9-15.8 months). Based on previous studies and exploratory analyses of 1- and 3-year OS, the ALBI score cut-off was set at -2.80. The 90 patients were divided into the ALBI-low (ALBI score <-2.80, n=29) and ALBI-high (ALBI score ≥-2.80, n=61) groups. The 1- and 3-year OS rates were 70.9% and 40.8% in the ALBI-low group and 35.5% and 13.7% in the ALBI-high group, respectively (

conclusionThe ALBI score may be a promising prognostic factor for patients with recurrent esophageal cancer.

Indexed as

BilirubinEsophageal NeoplasmsNeoplasm Recurrence, LocalSerum AlbuminAgedBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesBilirubinBiomarkers, TumorSerum AlbuminALBIesophageal cancerrecurrencesurvival

Identifiers

PMID42665427
PMCPMC13531142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.